What are the current pediatric transfusion protocols for packed red blood cells, platelets, and cryoprecipitate—including indications, weight‑based dosing, administration methods, monitoring, and detailed complications with their pathophysiology, definition, clinical presentation, diagnosis, and treatment—based on the latest American Academy of Pediatrics and Canadian Paediatric Society guidelines?

Comprehensive Review of Pediatric Transfusion Protocols

PACKED RED BLOOD CELLS (pRBCs)

Indications

For hemodynamically stable hospitalized children without hemoglobinopathy, cyanotic cardiac disease, or severe hypoxemia, transfuse when hemoglobin falls below 7 g/dL. 1

• Critically ill children and those at risk of critical illness: Restrictive threshold of 7 g/dL (strong recommendation, moderate certainty evidence) 1
• Cardiac surgery patients: May use threshold of 7.5 g/dL 1
• Orthopedic surgery or preexisting cardiovascular disease: May use threshold of 8 g/dL 1
• Congenital heart disease (hemodynamically stable): 1
  • Biventricular repair: 7 g/dL
  • Single-ventricle palliation: 9 g/dL
  • Uncorrected congenital heart disease: 7-9 g/dL
• Very preterm neonates (<30 weeks gestation): Use low transfusion thresholds as high thresholds show no benefit for mortality, bronchopulmonary dysplasia, severe intraventricular hemorrhage, retinopathy of prematurity, or neurodevelopmental outcomes at 2 years 2

Dosing

Standard transfusion volume: 10-20 mL/kg administered over 2-4 hours 2, 3

• Most common volumes used in clinical trials: 10 mL/kg, 15 mL/kg, or 20 mL/kg 2
• Expected hemoglobin increase: Approximately 2-3 g/dL per 10 mL/kg transfused 3
• Median transfusion duration in European NICUs: 4 hours (IQR 3-4 hours) 2

Administration Methods

Administer through appropriate vascular access with inline filter (170-260 micron standard blood filter) 3

• Warming: Use blood warmer for rapid transfusions, exchange transfusions, or large volume transfusions (>15 mL/kg/hour) 3
• Rate: Typically 5 mL/kg/hour for stable patients; may increase to 10-20 mL/kg/hour if clinically indicated 3
• Special populations - neonates: Small aliquots from single donor unit to minimize donor exposure 3
• Irradiation required for: Intrauterine transfusions, immunocompromised patients, directed donations from blood relatives, HLA-matched products 3
• Leukoreduction: Standard practice to reduce febrile reactions, CMV transmission, and alloimmunization 3

Monitoring

Obtain baseline vital signs, then monitor every 15 minutes for first hour, then hourly until completion 3

• Pre-transfusion assessment: 3
  • Hemoglobin/hematocrit
  • Vital signs (temperature, heart rate, blood pressure, respiratory rate, oxygen saturation)
  • Clinical signs of anemia or volume overload
• During transfusion: 3
  • Continuous observation for first 15 minutes (highest risk period for acute reactions)
  • Vital signs as above
  • Signs of transfusion reactions
• Post-transfusion: 3
  • Vital signs 15 minutes after completion
  • Hemoglobin check 15 minutes to 1 hour post-transfusion if clinically indicated
  • Document transfusion completion and patient tolerance

Complications

Transfusion-Associated Circulatory Overload (TACO)

Pathophysiology: Hydrostatic pulmonary edema from rapid volume expansion exceeding cardiac capacity, leading to increased pulmonary capillary pressure and fluid extravasation into alveoli 3

Definition: New or worsening pulmonary edema within 6-12 hours of transfusion with evidence of positive fluid balance and elevated brain natriuretic peptide (BNP) 3

Presentation: 3

• Acute respiratory distress (dyspnea, tachypnea, orthopnea)
• Hypertension (key distinguishing feature from TRALI)
• Tachycardia
• Elevated jugular venous pressure
• Pulmonary rales/crackles
• Hypoxemia
• Cyanosis in severe cases

Diagnosis: 3

• Clinical presentation within 6-12 hours of transfusion
• Chest radiograph showing bilateral pulmonary edema, cardiomegaly, pleural effusions
• Elevated BNP or NT-proBNP
• Positive fluid balance
• Elevated central venous pressure if monitored
• Echocardiography may show ventricular dysfunction

Treatment: 3

• Immediate: Stop transfusion immediately
• Respiratory support: Supplemental oxygen, non-invasive ventilation (CPAP/BiPAP), or mechanical ventilation as needed
• Diuretics: Furosemide 0.5-1 mg/kg IV (first-line therapy)
• Position: Elevate head of bed, upright positioning
• Monitoring: Strict intake/output, daily weights, continuous cardiorespiratory monitoring
• Prevention for future transfusions: Slower infusion rates (1-2 mL/kg/hour), smaller volumes, diuretics before/during transfusion in high-risk patients

Transfusion-Related Acute Lung Injury (TRALI)

Pathophysiology: Antibody-mediated (donor anti-HLA or anti-HNA antibodies) or non-antibody-mediated activation of recipient neutrophils in pulmonary vasculature, causing capillary leak and non-cardiogenic pulmonary edema 3

Definition: New acute lung injury (ALI) within 6 hours of transfusion with hypoxemia (PaO2/FiO2 <300 or SpO2 <90% on room air) and bilateral pulmonary infiltrates without evidence of circulatory overload 3

Presentation: 3

• Acute onset within 1-6 hours (typically within 1-2 hours)
• Severe dyspnea and tachypnea
• Hypoxemia (often severe, requiring mechanical ventilation in 70-80% of cases)
• Hypotension or normotension (distinguishes from TACO)
• Fever (38-40°C)
• Frothy pink or blood-tinged sputum
• Bilateral pulmonary infiltrates on chest radiograph

Diagnosis: 3

• Clinical presentation within 6 hours of transfusion
• Chest radiograph: Bilateral infiltrates without cardiomegaly
• Hypoxemia: PaO2/FiO2 ratio <300 mmHg
• Normal BNP/NT-proBNP (excludes TACO)
• Normal or low central venous pressure
• No temporal relationship to alternative ALI risk factors
• Laboratory: Test donor plasma for anti-HLA or anti-HNA antibodies

Treatment: 3

• Immediate: Stop transfusion immediately, do NOT administer diuretics (contraindicated)
• Respiratory support: High-flow oxygen, mechanical ventilation with lung-protective strategies (tidal volume 6 mL/kg ideal body weight, PEEP titration)
• Supportive care: Maintain adequate perfusion, vasopressors if hypotensive (norepinephrine preferred)
• Avoid fluid overload: Judicious fluid management
• Corticosteroids: No proven benefit, not routinely recommended
• Prognosis: Most cases resolve within 48-96 hours with supportive care; mortality 5-10% in pediatrics
• Prevention: Use male-only plasma or plasma from females without history of pregnancy

Febrile Non-Hemolytic Transfusion Reaction (FNHTR)

Pathophysiology: Recipient antibodies against donor leukocyte antigens or cytokines accumulated in stored blood products causing fever without hemolysis 3

Definition: Temperature rise ≥1°C (≥1.8°F) during or within 4 hours of transfusion without other identifiable cause 3

Presentation: 3

• Fever: Temperature ≥38°C or rise ≥1°C from baseline
• Chills and rigors
• Discomfort, malaise
• Headache
• No hemolysis (distinguishes from acute hemolytic reaction)
• No hypotension (distinguishes from severe reactions)

Diagnosis: 3

• Clinical diagnosis: Temperature elevation during or within 4 hours of transfusion
• Rule out hemolysis: Check visual inspection of plasma (no hemoglobinemia), direct antiglobulin test (negative), bilirubin (normal)
• Rule out bacterial contamination: Blood cultures from patient and blood product if suspected
• No other source of fever identified

Treatment: 3

• Immediate: Stop transfusion, maintain IV access, notify blood bank
• Antipyretics: Acetaminophen 10-15 mg/kg PO/IV every 4-6 hours (maximum 75 mg/kg/day or 4 g/day)
• Supportive care: Monitor vital signs every 15 minutes until stable
• Resume transfusion: May resume slowly after fever resolves if no other concerning signs
• Prevention for future transfusions: Premedicate with acetaminophen 30-60 minutes before transfusion, use leukoreduced blood products (reduces incidence by 50-90%)

Acute Hemolytic Transfusion Reaction (AHTR)

Pathophysiology: ABO incompatibility (most common) or other red cell antibodies cause intravascular hemolysis via complement activation, releasing free hemoglobin, causing renal injury, DIC, and shock 3

Definition: Hemolysis occurring during or within 24 hours of transfusion due to antibody-antigen incompatibility 3

Presentation: 3

• Early signs (within minutes to hours):
  • Fever and chills
  • Anxiety, sense of impending doom
  • Chest pain, back pain, flank pain
  • Dyspnea
  • Hypotension (may progress to shock)
  • Tachycardia
• Later signs:
  • Hemoglobinuria (dark red/brown urine)
  • Oliguria/anuria (acute kidney injury)
  • Bleeding (disseminated intravascular coagulation)
  • Jaundice
• In anesthetized patients: Unexplained hypotension, bleeding, hemoglobinuria may be only signs

Diagnosis: 3

• Immediate laboratory tests:
  • Visual inspection: Pink/red plasma (hemoglobinemia)
  • Direct antiglobulin test (DAT/Coombs): Positive
  • Plasma free hemoglobin: Elevated
  • Haptoglobin: Decreased or absent
  • Lactate dehydrogenase (LDH): Markedly elevated
  • Indirect bilirubin: Elevated (peaks 5-7 hours post-reaction)
• Confirm compatibility error:
  • Repeat ABO/Rh typing of patient and donor unit
  • Repeat crossmatch
  • Check clerical records for identification errors
• Assess complications:
  • Coagulation panel: PT, aPTT, fibrinogen, D-dimer (evaluate for DIC)
  • Renal function: Creatinine, BUN, urinalysis
  • Complete blood count

Treatment: 3

• Immediate actions:
  • Stop transfusion immediately, maintain IV access with normal saline
  • Notify blood bank and physician immediately
  • Send blood samples and donor unit to blood bank
• Maintain renal perfusion:
  • Aggressive IV fluid resuscitation: Normal saline 10-20 mL/kg bolus, then 1.5-2 times maintenance
  • Goal urine output: >1-2 mL/kg/hour
  • Furosemide 0.5-1 mg/kg IV if adequate volume status but poor urine output
  • Consider mannitol 0.5 g/kg IV (controversial, may use if oliguria persists)
• Treat hypotension:
  • Fluid resuscitation as above
  • Vasopressors if refractory (norepinephrine, dopamine)
• Manage DIC if present:
  • Fresh frozen plasma 10-15 mL/kg for coagulopathy with bleeding
  • Cryoprecipitate 1 unit/10 kg if fibrinogen <100 mg/dL
  • Platelet transfusion if platelets <50,000/μL with bleeding
• Monitoring:
  • Continuous cardiorespiratory monitoring
  • Hourly urine output
  • Serial laboratory tests: CBC, coagulation panel, renal function every 4-6 hours initially
• Renal replacement therapy: Hemodialysis or continuous renal replacement therapy if acute kidney injury with oliguria/anuria unresponsive to medical management

Delayed Hemolytic Transfusion Reaction (DHTR)

Pathophysiology: Anamnestic antibody response to red cell antigens (typically Rh, Kidd, Duffy systems) in previously sensitized patient, causing extravascular hemolysis 3-21 days post-transfusion 3

Definition: Hemolysis occurring 3-21 days after transfusion due to secondary immune response against transfused red cells 3

Presentation: 3

• Often asymptomatic or mild symptoms
• Unexplained decrease in hemoglobin/hematocrit
• Jaundice (scleral icterus)
• Dark urine (hemoglobinuria less common than AHTR)
• Fever (low-grade)
• Mild back or flank pain
• Inadequate hemoglobin increment post-transfusion

Diagnosis: 3

• Timing: 3-21 days post-transfusion (typically 7-10 days)
• Laboratory findings:
  • New positive direct antiglobulin test (DAT)
  • New red cell alloantibody detected in serum
  • Decreased hemoglobin from post-transfusion level
  • Elevated indirect bilirubin
  • Elevated LDH
  • Decreased haptoglobin
  • Positive antibody screen (previously negative)
• Distinguish from other causes: Rule out bleeding, ongoing hemolysis from underlying disease

Treatment: 3

• Most cases: Observation only, self-limited
• Symptomatic anemia: Transfuse antigen-negative, crossmatch-compatible red cells
• Supportive care: Hydration, monitor renal function
• Severe cases (rare): Treat as acute hemolytic reaction with aggressive hydration
• Prevention: Document antibody in patient record, provide patient with antibody identification card, ensure future transfusions are antigen-negative for identified antibody

Transfusion-Associated Graft-Versus-Host Disease (TA-GVHD)

Pathophysiology: Viable donor T-lymphocytes engraft in immunocompromised recipient, recognize host tissues as foreign, and mount immune attack against recipient tissues (skin, liver, GI tract, bone marrow) 3

Definition: Engraftment of donor lymphocytes causing multi-organ immune-mediated injury, typically 8-10 days post-transfusion (range 2-30 days) 3

Presentation: 3

• Onset: 8-10 days post-transfusion (range 2-30 days)
• Skin (most common initial manifestation):
  • Maculopapular rash starting on trunk, palms, soles
  • Progresses to generalized erythroderma
  • Bullae formation in severe cases
• Gastrointestinal:
  • Severe watery or bloody diarrhea (>1 L/day)
  • Nausea, vomiting
  • Abdominal pain, cramping
  • Anorexia
• Hepatic:
  • Elevated liver enzymes (AST, ALT, alkaline phosphatase)
  • Hyperbilirubinemia
  • Hepatomegaly
• Bone marrow (distinguishes from HSCT-GVHD):
  • Pancytopenia (severe, progressive)
  • Aplastic anemia
• Constitutional: Fever, malaise

Diagnosis: 3

• Clinical presentation: Characteristic triad of rash, diarrhea, liver dysfunction 8-10 days post-transfusion
• Laboratory findings:
  • Pancytopenia (thrombocytopenia, leukopenia, anemia)
  • Elevated liver enzymes, bilirubin
  • Elevated LDH
• Confirmatory tests:
  • Skin biopsy: Vacuolar interface dermatitis, lymphocytic infiltration, keratinocyte apoptosis
  • Bone marrow biopsy: Hypoplasia or aplasia
  • Chimerism studies: Detect donor lymphocytes in recipient blood (HLA typing, DNA fingerprinting)
• Differential diagnosis: Drug reaction, viral exanthem, HSCT-GVHD (if applicable)

Treatment: 3

• Prognosis: Mortality >90%, usually fatal within 3-4 weeks due to infection and bleeding from pancytopenia
• Immunosuppression (limited efficacy):
  • High-dose corticosteroids: Methylprednisolone 2 mg/kg/day IV
  • Cyclosporine or tacrolimus
  • Anti-thymocyte globulin (ATG) in refractory cases
• Supportive care:
  • Broad-spectrum antibiotics for neutropenic fever
  • Antifungal prophylaxis
  • Irradiated, leukoreduced blood product support
  • Growth factors: G-CSF 5-10 mcg/kg/day
  • Nutritional support (often requires parenteral nutrition)
  • Skin care: Emollients, wound care for bullae
• Experimental therapies: Mesenchymal stem cells, extracorporeal photopheresis (case reports only)
• Prevention (critical):
  • Irradiate blood products (25 Gy) for high-risk patients:
    • Congenital immunodeficiency syndromes
    • Hematopoietic stem cell transplant recipients (before and after transplant)
    • Hodgkin lymphoma patients
    • Intrauterine transfusions and neonates who received intrauterine transfusions
    • Directed donations from blood relatives
    • HLA-matched or crossmatched platelets
    • Patients receiving purine analogs (fludarabine, cladribine)

---

PLATELET TRANSFUSIONS

Indications

Platelet transfusions are indicated for prevention of bleeding in thrombocytopenic patients or treatment of active bleeding with thrombocytopenia or platelet dysfunction 4, 5

Prophylactic Transfusion Thresholds (Non-Bleeding Patients)

• Stable, non-bleeding patients: 10,000/μL 4, 5
• Fever, infection, or minor bleeding: 20,000/μL 4, 5
• Invasive procedures: 4, 5
  • Central line placement: 20,000/μL
  • Lumbar puncture: 40,000-50,000/μL
  • Major surgery: 50,000/μL
  • Neurosurgery or ophthalmologic surgery: 100,000/μL
• Active bleeding: 50,000/μL 4, 5
• Massive hemorrhage or CNS bleeding: 100,000/μL 4, 5
• Neonates: 4, 5
  • Stable preterm infant: 25,000/μL
  • Sick preterm infant (respiratory support, sepsis): 50,000/μL
  • Active bleeding or pre-procedure: 50,000-100,000/μL

Therapeutic Transfusion (Active Bleeding)

• Platelet count <50,000/μL with active bleeding 4, 5
• Platelet dysfunction with bleeding regardless of count (uremia, antiplatelet medications, congenital platelet disorders) 4, 5
• Massive transfusion protocol: Maintain platelets >50,000-100,000/μL 6, 4

Dosing

Standard dose: 10-20 mL/kg (approximately 5-10 mL/kg for apheresis platelets) 4, 5, 3

• Expected platelet increment: 3
  • 50,000-100,000/μL per standard dose in children
  • 5,000-10,000/μL per mL/kg transfused
• Calculation for desired increment: 3
  • Dose (units) = (Desired increment × Blood volume in L × Body surface area) / Expected increment per unit
  • Simplified: 1 unit/10 kg body weight or 10 mL/kg
• Neonates and small infants: 10-15 mL/kg 3
• Older children and adolescents: 5-10 mL/kg or 1 apheresis unit 3

Administration Methods

Administer through standard blood filter (170-260 micron) over 30-60 minutes 3

• Rate: As rapidly as tolerated, typically over 30-60 minutes (faster than pRBC transfusion) 3
• Do NOT use microaggregate filters: Will trap platelets 3
• ABO compatibility: ABO-identical preferred; ABO-compatible acceptable 3
  • If ABO-incompatible necessary, volume-reduce to remove incompatible plasma
• Rh compatibility: 3
  • Rh-positive platelets acceptable for Rh-negative recipients (platelets lack Rh antigen)
  • Consider Rh immunoglobulin for Rh-negative females of childbearing potential receiving Rh-positive platelets
• Special products: 3
  • HLA-matched platelets for alloimmunized patients (refractoriness)
  • Irradiated for immunocompromised patients
  • CMV-negative or leukoreduced for CMV-negative immunocompromised patients
• Storage: Room temperature (20-24°C) with continuous agitation; do NOT refrigerate 3

Monitoring

Assess platelet count 10-60 minutes and 18-24 hours post-transfusion to evaluate response 3

• Pre-transfusion: 3
  • Platelet count
  • Vital signs
  • Assess for active bleeding
• During transfusion: 3
  • Vital signs every 15 minutes
  • Monitor for transfusion reactions (allergic reactions more common with platelets due to plasma content)
• Post-transfusion: 3
  • Platelet count 10-60 minutes post-transfusion (1-hour corrected count increment)
  • Platelet count 18-24 hours post-transfusion (assess for refractoriness)
  • Vital signs
  • Assess bleeding symptoms
• Corrected count increment (CCI): 3
  • CCI = (Post-transfusion count - Pre-transfusion count) × BSA (m²) / Number of platelets transfused (×10¹¹)
  • CCI <7,500 at 1 hour or <4,500 at 24 hours suggests refractoriness

Complications

Platelet Refractoriness

Pathophysiology: Inadequate platelet count increment post-transfusion due to immune (HLA or HPA alloantibodies) or non-immune factors (fever, sepsis, splenomegaly, DIC, medications) 3

Definition: Corrected count increment (CCI) <7,500 at 1 hour or <4,500 at 24 hours on two consecutive transfusions 3

Presentation: 3

• Inadequate platelet count increment post-transfusion
• Persistent thrombocytopenia despite appropriate platelet transfusions
• May have bleeding despite transfusions
• No immediate transfusion reaction symptoms

Diagnosis: 3

• Calculate CCI: As above; CCI <7,500 at 1 hour suggests refractoriness
• Distinguish immune vs. non-immune causes:
  • Immune: HLA antibody testing (panel reactive antibody), HPA antibody testing
  • Non-immune factors to evaluate:
    • Fever, infection, sepsis
    • Splenomegaly (physical exam, ultrasound)
    • DIC (coagulation panel)
    • Medications (amphotericin, vancomycin)
    • Active bleeding
    • ABO incompatibility
• Timing: Immediate refractoriness (within 1 hour) suggests immune cause; delayed (24 hours) suggests non-immune

Treatment: 3

• Address non-immune factors:
  • Treat infection/sepsis
  • Discontinue offending medications if possible
  • Manage DIC
  • Use ABO-identical platelets
• Immune refractoriness:
  • HLA-matched platelets: First-line for HLA alloimmunization
  • Crossmatch-compatible platelets: If HLA-matched unavailable
  • Increase dose: Higher platelet doses may overcome low-titer antibodies
  • Increase frequency: More frequent transfusions to maintain hemostatic level
• Adjunctive therapies (limited evidence in pediatrics):
  • Intravenous immunoglobulin (IVIG) 1 g/kg may temporarily improve response
  • Platelet growth factors (thrombopoietin agonists) for chronic thrombocytopenia
• Prevention:
  • Use leukoreduced blood products to reduce HLA alloimmunization risk
  • Limit donor exposures when possible (apheresis platelets from single donor)

Allergic Transfusion Reactions

Pathophysiology: Type I hypersensitivity reaction to plasma proteins in platelet product, mediated by recipient IgE antibodies against donor plasma proteins 3

Definition: Urticaria, pruritus, or anaphylaxis occurring during or within 4 hours of transfusion 3

Presentation: 3

• Mild (most common):
  • Urticaria (hives), localized or generalized
  • Pruritus (itching)
  • Flushing
  • No respiratory or hemodynamic compromise
• Moderate:
  • Extensive urticaria
  • Facial or periorbital edema
  • Mild bronchospasm (wheezing)
• Severe (anaphylaxis, rare):
  • Respiratory distress (bronchospasm, laryngeal edema, stridor)
  • Hypotension, shock
  • Gastrointestinal symptoms (nausea, vomiting, diarrhea, abdominal cramping)
  • Loss of consciousness
  • Cardiovascular collapse

Diagnosis: 3

• Clinical diagnosis: Characteristic symptoms during or within 4 hours of transfusion
• Mild reactions: Isolated urticaria/pruritus without systemic symptoms
• Anaphylaxis: Acute onset with skin/mucosal involvement PLUS respiratory compromise and/or hypotension
• Laboratory (for severe reactions):
  • Serum tryptase (elevated in anaphylaxis, peak 1-2 hours post-reaction)
  • IgA level (if recurrent severe reactions, consider IgA deficiency with anti-IgA antibodies)
• Rule out other causes: Hemolytic reaction (check for hemolysis), bacterial contamination (fever, hypotension)

Treatment: 3

• Mild (urticaria only):
  • Slow or stop transfusion temporarily
  • Antihistamine: Diphenhydramine 1 mg/kg IV/PO (maximum 50 mg)
  • May resume transfusion slowly if symptoms resolve and no progression
• Moderate:
  • Stop transfusion, maintain IV access
  • Antihistamine: Diphenhydramine 1 mg/kg IV (maximum 50 mg)
  • H2-blocker: Ranitidine 1 mg/kg IV or famotidine 0.25 mg/kg IV
  • Corticosteroid: Methylprednisolone 1-2 mg/kg IV
  • Monitor closely; do not resume transfusion
• Severe (anaphylaxis):
  • Stop transfusion immediately, maintain IV access
  • Epinephrine 0.01 mg/kg (0.01 mL/kg of 1:1000) IM (anterolateral thigh), maximum 0.5 mg; repeat every 5-15 minutes as needed
  • Position supine with legs elevated (if hypotensive)
  • High-flow oxygen, secure airway if needed
  • IV fluid bolus: Normal saline 20 mL/kg rapidly
  • Antihistamines: Diphenhydramine 1 mg/kg IV
  • Corticosteroid: Methylprednisolone 1-2 mg/kg IV
  • Bronchodilators: Albuterol nebulizer if bronchospasm
  • Vasopressors if refractory hypotension (epinephrine infusion)
  • Admit for observation (biphasic reactions can occur 4-12 hours later)
• Prevention for future transfusions:
  • Premedicate with antihistamine 30-60 minutes before transfusion
  • Washed platelets (remove plasma) for recurrent moderate-severe reactions
  • IgA-deficient products if anti-IgA antibodies identified

Bacterial Contamination/Sepsis

Pathophysiology: Bacterial contamination of platelet product (stored at room temperature, ideal for bacterial growth) causing sepsis when transfused; most common organisms are skin flora (Staphylococcus, Streptococcus) or gram-negative rods (Escherichia coli, Klebsiella, Serratia) 3

Definition: Acute onset of fever, chills, hypotension, and/or shock during or within 4 hours of platelet transfusion due to bacterial contamination of product 3

Presentation: 3

• Acute onset during or immediately after transfusion:
  • High fever (>39°C), often with rigors
  • Severe chills, shaking
  • Hypotension, shock (may be profound)
  • Tachycardia
  • Nausea, vomiting
  • Dyspnea
  • Altered mental status
• Rapid progression: Symptoms escalate quickly, may progress to septic shock within minutes to hours
• Product appearance: May appear cloudy, discolored, or have visible clumps (but often appears normal)

Diagnosis: 3

• High index of suspicion: Fever >39°C with hypotension during platelet transfusion
• Immediate actions:
  • Stop transfusion, maintain IV access
  • Blood cultures from patient (two sets from different sites)
  • Culture platelet product (send entire bag to blood bank and microbiology)
  • Gram stain of platelet product
• Laboratory findings:
  • Leukocytosis or leukopenia
  • Elevated lactate (sepsis)
  • Coagulopathy (DIC may develop)
  • Positive blood cultures (patient and/or product)
• Distinguish from other reactions: Hemolytic reaction (check for hemolysis), TRALI (chest X-ray), allergic reaction (no hypotension typically)

Treatment: 3

• Immediate resuscitation:
  • Stop transfusion immediately
  • Aggressive IV fluid resuscitation: Normal saline 20 mL/kg bolus, repeat as needed
  • Vasopressors if fluid-refractory hypotension (norepinephrine first-line)
  • Oxygen, respiratory support as needed
• Antibiotics (empiric, broad-spectrum):
  • Start immediately, do not wait for culture results
  • Vancomycin 15 mg/kg IV every 6 hours (covers gram-positive including MRSA)
  • PLUS ceftazidime 50 mg/kg IV every 8 hours OR cefepime 50 mg/kg IV every 8 hours (covers gram-negative)
  • Adjust based on culture results and sensitivities
• Supportive care:
  • Continuous cardiorespiratory monitoring
  • ICU admission
  • Treat DIC if develops (FFP, cryoprecipitate, platelets as indicated)
  • Renal support if acute kidney injury
• Monitoring:
  • Serial vital signs, lactate, blood cultures
  • Coagulation panel, renal function
• Prevention:
  • Bacterial detection systems for platelet products
  • Strict aseptic technique during collection
  • Limit platelet storage duration (5 days maximum)
  • Visual inspection before transfusion

Transfusion-Associated Dyspnea (TAD)

Pathophysiology: Acute respiratory distress during or within 24 hours of transfusion without meeting criteria for TRALI or TACO; mechanism unclear, possibly related to bioactive lipids or cytokines in stored blood products 3

Definition: Acute dyspnea during or within 24 hours of transfusion without evidence of TRALI, TACO, or allergic reaction 3

Presentation: 3

• Acute onset dyspnea, respiratory distress
• Tachypnea
• Hypoxemia (mild to moderate)
• No fever (distinguishes from FNHTR)
• No hypotension (distinguishes from anaphylaxis, sepsis)
• No pulmonary edema on chest X-ray (distinguishes from TRALI, TACO)
• Normal BNP (distinguishes from TACO)

Diagnosis: 3

• Diagnosis of exclusion: Rule out TRALI, TACO, allergic reaction, bacterial contamination
• Clinical presentation: Isolated dyspnea without other features
• Chest X-ray: Normal or minimal changes
• BNP/NT-proBNP: Normal
• Oxygen saturation: Decreased but typically not severe

Treatment: 3

• Stop transfusion
• Supplemental oxygen to maintain SpO2 >92%
• Supportive care, observation
• Usually self-limited, resolves within hours
• May resume transfusion slowly if symptoms resolve
• No specific therapy required

---

CRYOPRECIPITATE

Indications

Cryoprecipitate is indicated for fibrinogen replacement in bleeding patients with hypofibrinogenemia (<100-150 mg/dL) or dysfibrinogenemia 4, 5

• Hypofibrinogenemia with active bleeding: Fibrinogen <100 mg/dL 4, 5
• Massive transfusion/trauma: Maintain fibrinogen >150-200 mg/dL 6, 4, 5
• Disseminated intravascular coagulation (DIC) with bleeding: Fibrinogen <100 mg/dL 4, 5
• Congenital fibrinogen disorders: Afibrinogenemia, hypofibrinogenemia, dysfibrinogenemia with bleeding 4, 5
• Uremic bleeding (alternative to DDAVP/dialysis): Contains von Willebrand factor 5
• Von Willebrand disease (if specific concentrates unavailable): Contains vWF and Factor VIII 5
• Hemophilia A (if Factor VIII concentrate unavailable): Contains Factor VIII 5
• Factor XIII deficiency (if specific concentrate unavailable): Contains Factor XIII 5

Dosing

Standard dose: 1-2 units (bags) per 10 kg body weight or 5-10 mL/kg 4, 5

• Expected fibrinogen increment: 4, 5
  • Each unit contains approximately 150-250 mg fibrinogen
  • 1 unit/10 kg raises fibrinogen by approximately 60-100 mg/dL
• Target fibrinogen level: 4, 5
  • Active bleeding: >100 mg/dL (some sources recommend >150 mg/dL)
  • Massive transfusion/trauma: >150-200 mg/dL
  • Surgical hemostasis: >100 mg/dL
• Calculation for desired increment: 4, 5
  • Dose (units) = [(Target fibrinogen - Current fibrinogen) × Plasma volume] / Fibrinogen content per unit
  • Simplified: 1-2 units/10 kg or 5-10 mL/kg
• Neonates: 5-10 mL/kg 5
• Massive transfusion protocol: 1-2 units/10 kg initially, repeat based on fibrinogen levels 6, 4

Administration Methods

Thaw at 30-37°C, administer through standard blood filter over 30-60 minutes 5, 3

• Preparation: 5, 3
  • Thaw in 30-37°C water bath for 10-15 minutes
  • Once thawed, must be transfused within 4-6 hours
  • Pool multiple units for single infusion if needed
• Rate: Administer over 30-60 minutes (may give faster in emergency) 5, 3
• Filter: Standard blood filter (170-260 micron) 3
• ABO compatibility: ABO-compatible preferred (contains small amount of RBCs); Rh compatibility not required 3
• Special considerations: 5, 3
  • Contains Factor VIII and vWF (useful in hemophilia A, vWD if specific concentrates unavailable)
  • Contains Factor XIII
  • Contains fibronectin
  • Small volume (10-15 mL per unit), concentrated source of fibrinogen

Monitoring

Check fibrinogen level before and 1 hour after transfusion to assess response 4, 5

• Pre-transfusion: 4, 5
  • Fibrinogen level
  • Complete coagulation panel (PT, aPTT, platelets)
  • Vital signs
  • Assess bleeding
• During transfusion: 5, 3
  • Vital signs every 15 minutes
  • Monitor for transfusion reactions
• Post-transfusion: 4, 5
  • Fibrinogen level 1 hour post-transfusion (assess increment)
  • Repeat coagulation panel if indicated
  • Assess bleeding status
  • Vital signs
• Ongoing monitoring in massive transfusion: 6, 4
  • Fibrinogen level every 30-60 minutes during active resuscitation
  • Goal fibrinogen >150-200 mg/dL

Complications

Fibrinogen Concentrate as Alternative

Pathophysiology: Viral-inactivated, purified fibrinogen concentrate offers advantages over cryoprecipitate: standardized fibrinogen content, no ABO matching required, rapid reconstitution, viral inactivation 4, 5

Definition: Purified, lyophilized fibrinogen product (RiaSTAP, Fibryga) approved for congenital fibrinogen deficiency; increasingly used off-label for acquired hypofibrinogenemia 4, 5

Presentation: Not a complication but an alternative therapy; consider when: 4, 5

• Cryoprecipitate unavailable
• Need for rapid fibrinogen replacement
• Concern for volume overload (smaller volume than cryoprecipitate)
• Congenital fibrinogen deficiency (FDA-approved indication)

Diagnosis: N/A (therapeutic option)

Treatment/Dosing: 4, 5

• Dose: 70 mg/kg IV (for congenital deficiency)
• Off-label dosing for acquired hypofibrinogenemia: 3-4 g (or 50-70 mg/kg) IV
• Expected increment: 70 mg/kg raises fibrinogen by approximately 100 mg/dL
• Administration: Reconstitute with sterile water, administer IV over 5-10 minutes
• Advantages: Standardized dose, rapid administration, viral inactivation, no ABO matching
• Disadvantages: Cost (significantly more expensive than cryoprecipitate), limited availability

Allergic Reactions (Same as Platelet Transfusions)

Pathophysiology, Definition, Presentation, Diagnosis, Treatment: See Platelet Transfusions - Allergic Reactions section above 3

• Cryoprecipitate contains plasma proteins and can cause allergic reactions identical to those from platelet or plasma transfusions 3

Transfusion-Associated Circulatory Overload (TACO)

Pathophysiology, Definition, Presentation, Diagnosis, Treatment: See pRBC Transfusions - TACO section above 3

• Less common with cryoprecipitate due to small volume per unit (10-15 mL), but can occur if multiple units transfused rapidly 3

Viral Transmission (Rare with Modern Screening)

Pathophysiology: Cryoprecipitate is derived from plasma and theoretically carries risk of transfusion-transmitted infections (HIV, hepatitis B, hepatitis C, other viruses) 3

Definition: Transmission of viral infection through transfusion of contaminated blood product 3

Presentation: 3

• Acute (rare): Fever, malaise within days to weeks
• Chronic: Hepatitis (jaundice, elevated liver enzymes), HIV seroconversion (weeks to months post-transfusion)
• Most infections asymptomatic initially

Diagnosis: 3

• Serologic testing for HIV, hepatitis B, hepatitis C
• Nucleic acid testing (NAT) for viral RNA/DNA
• Lookback investigation if donor subsequently tests positive

Treatment: 3

• Hepatitis B: Antiviral therapy (tenofovir, entecavir) if chronic infection develops
• Hepatitis C: Direct-acting antivirals (sofosbuvir-based regimens)
• HIV: Antiretroviral therapy
• Prevention (most important):
  • Rigorous donor screening and testing (NAT for HIV, HCV, HBV)
  • Pathogen reduction technologies (not yet standard for cryoprecipitate)
  • Risk with modern screening: HIV 1 in 1-2 million, HCV 1 in 1-2 million, HBV 1 in 300,000-500,000

Thrombotic Complications (Theoretical)

Pathophysiology: Cryoprecipitate contains high concentrations of fibrinogen, Factor VIII, vWF, and Factor XIII; excessive replacement may theoretically increase thrombotic risk, though rarely reported in pediatrics 4, 5

Definition: Thrombosis (venous or arterial) temporally related to cryoprecipitate transfusion in setting of supraphysiologic fibrinogen levels 4, 5

Presentation: 4, 5

• Deep vein thrombosis (leg swelling, pain, erythema)
• Pulmonary embolism (dyspnea, chest pain, hypoxemia)
• Arterial thrombosis (rare; stroke, myocardial infarction)
• Catheter-associated thrombosis

Diagnosis: 4, 5

• Clinical suspicion based on symptoms
• Doppler ultrasound for DVT
• CT pulmonary angiography for PE
• Fibrinogen level (if markedly elevated >400-500 mg/dL, may contribute)
• D-dimer (elevated in thrombosis)

Treatment: 4, 5

• Anticoagulation: Enoxaparin 1 mg/kg subcutaneous every 12 hours or unfractionated heparin infusion
• Supportive care
• Prevention: Avoid excessive fibrinogen replacement; target physiologic levels (100-200 mg/dL), not supraphysiologic

---

MASSIVE TRANSFUSION PROTOCOL IN PEDIATRICS

Definition and Activation

Massive transfusion is defined as transfusion of ≥40 mL/kg of blood products within 24 hours or replacement of one blood volume within 24 hours 6

• Activation criteria: 6
  • Anticipated need for ≥40 mL/kg blood products
  • Ongoing hemorrhage requiring resuscitation
  • Hemodynamic instability despite initial resuscitation
  • Trauma with significant mechanism and evidence of hemorrhage

Balanced Resuscitation Ratios

Maintain 1:1:1 ratio of pRBC:FFP:platelets (or 1:1 pRBC:FFP with platelet support) to prevent dilutional coagulopathy 6, 4

• Goal ratios: 6
  • pRBC:FFP ratio of 1:1 (improved from historical 3:1 with implementation of dose books)
  • Platelet transfusion to maintain count >50,000-100,000/μL
  • Cryoprecipitate to maintain fibrinogen >150-200 mg/dL
• Pediatric massive transfusion protocol dose book: Weight-based guide improves adherence to balanced ratios (average ratio improved from 3.38:1 to 1.37:1 post-implementation) 6

Laboratory Monitoring During Massive Transfusion

Check CBC, coagulation panel (PT, aPTT, fibrinogen), ionized calcium, and blood gas every 30-60 minutes during active resuscitation 6, 4

• Initial labs: Type and crossmatch, CBC, PT/aPTT/INR, fibrinogen, platelets, blood gas, lactate, ionized calcium 6, 4
• Repeat every 30-60 minutes: 6, 4
  • Hemoglobin/hematocrit
  • Platelet count
  • PT, aPTT, fibrinogen
  • Ionized calcium (citrate toxicity from massive transfusion)
  • Lactate (tissue perfusion marker)
  • Blood gas (acidosis)
• Targets: 6, 4
  • Hemoglobin >7-8 g/dL
  • Platelets >50,000-100,000/μL
  • Fibrinogen >150-200 mg/dL
  • INR <1.5
  • Ionized calcium >1.0 mmol/L
  • pH >7.2

Complications Specific to Massive Transfusion

Citrate Toxicity/Hypocalcemia

Pathophysiology: Citrate anticoagulant in blood products binds ionized calcium, causing hypocalcemia; exacerbated by rapid transfusion, liver dysfunction (impaired citrate metabolism), hypothermia 4

Definition: Ionized calcium <1.0 mmol/L during or after massive transfusion 4

Presentation: 4

• Paresthesias (perioral, extremities)
• Muscle cramps, tetany
• Prolonged QT interval on ECG
• Cardiac arrhythmias (bradycardia, ventricular arrhythmias)
• Hypotension (impaired cardiac contractility)
• Seizures (severe cases)

Diagnosis: 4

• Ionized calcium level <1.0 mmol/L (normal 1.1-1.3 mmol/L)
• ECG: Prolonged QT interval
• Clinical signs as above

Treatment: 4

• Calcium replacement:
  • Calcium chloride 10-20 mg/kg IV (0.1-0.2 mL/kg of 10% solution) over 5-10 minutes
  • OR calcium gluconate 30-60 mg/kg IV (0.3-0.6 mL/kg of 10% solution) over 5-10 minutes
  • Calcium chloride preferred (provides more elemental calcium)
• Repeat dosing: Based on ionized calcium levels every 30-60 minutes
• Continuous infusion: If persistent hypocalcemia, calcium chloride 10-50 mg/kg/hour or calcium gluconate 30-150 mg/kg/hour
• Prevention:
  • Monitor ionized calcium every 30-60 minutes during massive transfusion
  • Empiric calcium supplementation: 5-10 mg/kg calcium chloride per 100 mL blood product transfused

Hypothermia

Pathophysiology: Rapid transfusion of cold blood products (stored at 1-6°C for pRBCs) causes core hypothermia, which impairs coagulation enzyme function, platelet function, and cardiac function 4

Definition: Core temperature <35°C during or after massive transfusion 4

Presentation: 4

• Core temperature <35°C (mild), <32°C (moderate), <28°C (severe)
• Shivering (initially, ceases with severe hypothermia)
• Coagulopathy (impaired enzyme function)
• Cardiac arrhythmias (bradycardia, atrial fibrillation, ventricular fibrillation)
• Decreased cardiac output
• Altered mental status

Diagnosis: 4

• Core temperature measurement (rectal, esophageal, bladder)
• Temperature <35°C

Treatment: 4

• Active warming:
  • Warm IV fluids and blood products (blood warmer set to 37-42°C)
  • Forced-air warming blanket (Bair Hugger)
  • Increase ambient room temperature
  • Warm humidified oxygen
  • Warmed peritoneal or pleural lavage (severe cases)
  • Extracorporeal rewarming (ECMO) for severe refractory hypothermia
• Prevention (critical):
  • Use blood warmer for all rapid transfusions or large volumes (>15 mL/kg/hour)
  • Warm IV fluids
  • Forced-air warming blanket
  • Increase operating room/trauma bay temperature

Hyperkalemia

Pathophysiology: Stored pRBCs accumulate extracellular potassium due to red cell membrane pump dysfunction during storage; rapid transfusion of old blood can cause acute hyperkalemia, especially in neonates and patients with renal dysfunction 4, 3

Definition: Serum potassium >5.5 mmol/L (neonates >6.0 mmol/L) during or after massive transfusion 4, 3

Presentation: 4, 3

• Often asymptomatic
• Muscle weakness
• Cardiac arrhythmias (peaked T waves, widened QRS, bradycardia, ventricular fibrillation)
• Cardiac arrest (severe hyperkalemia >7-8 mmol/L)

Diagnosis: 4, 3

• Serum potassium >5.5 mmol/L
• ECG changes: Peaked T waves (earliest sign), prolonged PR interval, widened QRS, loss of P wave, sine wave pattern (pre-arrest)

Treatment: 4, 3

• Mild (5.5-6.5 mmol/L, no ECG changes):
  • Monitor closely
  • Slow transfusion rate
  • Ensure adequate urine output
• Moderate (6.5-7.5 mmol/L or ECG changes):
  • Calcium chloride 10-20 mg/kg IV over 5-10 minutes (cardiac membrane stabilization, does NOT lower potassium)
  • Insulin 0.1 units/kg IV with dextrose 0.5-1 g/kg IV (shifts potassium intracellularly)
  • Albuterol nebulizer 2.5-5 mg (shifts potassium intracellularly)
  • Sodium bicarbonate 1-2 mEq/kg IV if acidotic (shifts potassium intracellularly)
• Severe (>7.5 mmol/L or life-threatening arrhythmias):
  • Immediate calcium chloride 10-20 mg/kg IV
  • Insulin/dextrose as above
  • Consider dialysis if refractory
• Prevention:
  • Use fresher blood (<7-10 days old) for massive transfusion in neonates and high-risk patients
  • Wash pRBCs to remove extracellular potassium if very high risk
  • Monitor potassium every 30-60 minutes during massive transfusion